Core Healthcare Ltd.
BSE: 500091 | Sector: Health care |
NSE: COREPARENT | ISIN Code: INE494A01017 |
BSE 05:30 | 01 Jan | Core Healthcare Ltd |
NSE 05:30 | 01 Jan | Core Healthcare Ltd |
Core Healthcare Ltd. (COREPARENT) - News Sector
-
NCLT approves the demerger of Piramal Enterprises' pharma business
12.44 am | 13 Aug 2022 | Business Standard
This paves the way towards creation of two separate listed entities - Piramal Enterprises and Piramal Pharma
-
F&O Strategy: Nandish Shah recommends a Bull Spread on Lupin
8.27 am | 12 Aug 2022 | Business Standard
The technical analyst from HDFC Securities recommends buying Lupin 700 Call and simultaneously selling 720 Call for the August series.
-
Max Healthcare Q1 net profit up 12% at Rs 229 cr; revenue rises 5%
3.49 pm | 10 Aug 2022 | Press Trust of India
'Q1FY23 performance reflects normalisation of revenues and operating EBITDA post Omicron wave in the previous quarter,' Max Healthcare Chairman and MD...
-
Apollo Hospitals acquires asset from Nayati Healthcare for Rs 450 crore
1.56 am | 9 Aug 2022 | Business Standard
The hospital asset was sold by DLF Qutub Enclave Complex Medical Charitable Trust in 2011 to Nayati Healthcare and Research NCR Pvt Ltd
-
Lupin reports Q1 net loss at Rs 89 cr on lower US sales; revenue falls 12%
9.30 pm | 4 Aug 2022 | Press Trust of India
'Our numbers are muted this quarter, but we expect a strong bounce back from Q2 onwards,' says Lupin MD
-
Here's why Vinay Rajani recommends buying Indoco Remedies, PTC India
7.54 am | 3 Aug 2022 | Business Standard
The technical analyst from HDFC Securities said traders should wait for correction to enter fresh longs on the Nifty index.
-
We're geared to launch a new molecule every 1-2 years: Biocon Biologics MD
12.46 pm | 2 Aug 2022 | Business Standard
In an interview, Arun Chandravarkar explains why a company must continue investing in R&D despite the impact on short-term Ebitda
-
Piramal Group charts growth path for financial services business
3.46 pm | 1 Aug 2022 | Press Trust of India
'We are on track to achieve retail loan disbursements of Rs 2,500 cr-3,500 cr in Q3FY23,' which is 5-7 times of pre-merger levels, says Piramal Group ...
-
Sun Pharma stock likely to keep shining amid global specialty scale-up
11.48 pm | 31 Jul 2022 | Business Standard
Focus on key markets to help expand branded formulations business, say experts
-
Cipla Q1 net dips 4% to Rs 686 cr, revenue down 2% on tapering Covid sales
10.06 pm | 29 Jul 2022 | Business Standard
Domestic revenue dips 8.4% as Covid-19 share of branded prescription business normalises; North American business up 10% to $155 million
-
Sun Pharma Q1 net up 43% to Rs 2,061 crore on specialty sales, India biz
10.00 pm | 29 Jul 2022 | Business Standard
Gross sales up 10.1% YoY to Rs 10,644 cr; EBITDA at Rs 2,884.4 cr, with a margin of 26.8%
-
Top headlines: HDFC Q1 net rises 22%; IOC posts Rs 1,993-cr net loss in Q1
5.27 pm | 29 Jul 2022 | Business Standard
Swiggy announced on Friday that it has extended its 'Future of Work' policy and announced a permanent work-from-anywhere for majority of roles.
-
Cipla Q1 net profit dips marginally to Rs 706 cr; revenue falls 2%
4.30 pm | 29 Jul 2022 | Press Trust of India
The Mumbai-based company had reported a net profit of Rs 710 crore in the April-June quarter of the last fisca
-
Strong India growth boosts DRL Q1 profit by 108% to Rs 1,188 crore
11.37 pm | 28 Jul 2022 | Business Standard
The DRL stock was down marginally (0.73 per cent) to Rs 4,254 on the BSE on Thursday
-
Dr Reddy's Q1 PAT soars 108% to Rs 1,188 cr; revenue rises 6%
6.34 pm | 28 Jul 2022 | Press Trust of India
Other operating income was at Rs 600 crore compared to Rs 50 crore in Q1FY22
-
Top headlines: Dr Reddy's Q1 PAT up 108%; Adani Capital IPO likely in 2024
6.00 pm | 28 Jul 2022 | Business Standard
Bajaj Finserv on Thursday reported a 57 per cent jump in net profit at Rs 1,309 crore in the first quarter ended June 30, on healthy earnings by its s...
-
Sun Pharma's Q1 margins likely to be hit on elevated input costs: Analysts
12.51 pm | 28 Jul 2022 | Business Standard
Sun Pharma Q1FY23 results: Prabhudas Lilladher foresees the company's net profit to rise 27 per cent year-on-year (YoY) to Rs 1,786 crores from Rs 1,4...
-
Here's why Vinay Rajani recommends buying Ajanta Pharma, TTK Prestige
7.46 am | 27 Jul 2022 | Business Standard
The technical analyst also recommends to hold Nifty longs with a stop at 16,300; on the upside, he expects resistance for the NSE benchmark around 16,...
-
Fitch downgrades Jubilant Pharma to "BB-" indicating higher default risk
2.00 pm | 22 Jul 2022 | Business Standard
Rating agency foresees firm's financial leverage worsening as a rise in capex will coincide with lower profitability
-
Gland Pharma faces a revenue growth hurdle in FY23; stock falls
11.34 pm | 21 Jul 2022 | Business Standard
The low margin syringes business was impacted by supply chain challenges and shutdown of two manufacturing lines in the domestic market
Quick Links for Core Healthcare:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices